You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 3.1% | 3.9% |
Div Cover | 3.2 | 2.6 |
Op Mrgn | 21.9% | 27.9% |
ROCE | 61.0% |
Latest | Forecast | |
---|---|---|
P/E | 10.3 | 0.0 |
PEG | 0.4 | 3.7 |
Price / Revenue | 2.0 | 2.0 |
Price / Book value | 5.8 |
Latest | Forecast | |
---|---|---|
Revenue | 17.4% | -21.6% |
PBT | 56.4% | n/a |
EPS | 23.4% | 14.9% |
DPS | -56.0% | -1.4% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2018-12-31 | 30,821.00 | 4,800.00 | 119.40p | 15.6 | 2.3 | 7% | 80.00p | 4.3% |
2019-12-31 | 33,754.00 | 6,221.00 | 123.90p | 17.9 | 4.8 | 4% | 80.00p | 3.6% |
2020-12-31 | 34,099.00 | 6,968.00 | 115.90p | 14.5 | -2.2 | -6% | 80.00p | 4.8% |
2021-12-31 | 24,969.00 | 3,599.00 | 113.20p | 17.7 | -7.6 | -2% | 100.00p | 5.0% |
2022-12-31 | 29,324.00 | 5,628.00 | 139.70p | 10.3 | 0.4 | 23% | 44.00p | 3.1% |
FDA approves GSK anaemia drug Sharecast News | 02 Feb |
---|---|
Record vaccine sales boost profits at GSK Sharecast News | 01 Feb |
GSK plans return of HQ to central London in 2024 Sharecast News | 12 Dec |
Daprodustat approved by US FDA for anaemia of CKD | 02-Feb-23 14:10 |
---|---|
Director/PDMR Shareholding | 01-Feb-23 23:58 |
Total Voting Rights | 01-Feb-23 23:58 |
Benlysta granted Orphan Drug Designation by US FDA | 01-Feb-23 14:57 |
Final Results | 01-Feb-23 14:48 |